Our results indicate that GSK3326595, a PRMT5-specific inhibitor, is a potentially effective drug for reducing CRC immune evasion by blocking ALKBH5 methylation and ALKBH5–CD276 interaction. The gene discussed is CD276; the disease is colorectal carcinoma.